AI enhances therapeutic development by identifying drug targets and optimizing strategies for infectious diseases, suggesting significant advancements in healthcare.
Drug discovery and development for infectious diseases has transformed from phenotypic screening to rational design, and now embracing artificial intelligence (AI) to accelerate and optimize therapeutic development. We describe our use of AI to analyze vast and diverse data sets to generate therapeutic hypotheses and identify novel drug targets. We discuss generative design, active learning and automation. Finally we cover the use of AI in development. We believe that decoding biology and industrializing discovery through AI and automation is revolutionizing drug discovery in general, and has the potential to deliver improved patient outcomes and global health benefits in infectious diseases.
No takes yet. Share an insight, caveat, or question.
Bon et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: